News from decision resources group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 29, 2016, 02:30 ET Decision Resources Group Expands into Healthcare Payer Market

Decision Resources Group (DRG) today announced that it has acquired Adaptive Software (Adaptive), developers of market-leading pharmacy benefit and...


Jan 06, 2016, 08:30 ET Decision Resources Group Unifies Portfolio Under DRG Brand

Decision Resources Group (DRG) announced that it has unified its portfolio of best-in-class companies under one brand. "The healthcare industry is...


Dec 28, 2015, 08:30 ET Several Therapies to Launch for Hemophilia A, Hemophilia B and Hemophilia with Inhibitors in the U.S. and E.U. through 2025

Decision Resources Group forecasts that several therapies will launch for hemophilia A, hemophilia B and hemophilia with inhibitors in the United...


Dec 22, 2015, 08:30 ET The Rising Prevalence of Diabetes and its Confounding Complications

Decision Resources Group finds that the prevalent type 2 diabetes (T2D) population in the G7 (United States, France, Germany, Italy, Spain, United...


Dec 21, 2015, 08:30 ET Novel Agents Are Set To Reverse The Decline In The Osteoporosis Market

Decision Resources Group finds that, according to the Osteoporosis Pharmacor report, published December 2015, the osteoporosis market is expected to...


Dec 18, 2015, 08:30 ET The Launches of Novel Routine Prophylactic Agents with Improved Administration Convenience Will Reshape the Hereditary Angioedema Market

Decision Resources Group finds that the anticipated approvals of several prophylactic agents, including BioCryst's avoralstat and BCX-7353, Dyax's...


Dec 17, 2015, 08:30 ET The Global Structural Heart Closure Device Market will Experience Strong Growth Through 2024, Driven Primarily by the Uptake of Endocardial LAA Closure for Stroke Prevention in Atrial Fibrillation Patients

Decision Resources Group finds that the global structural heart closure device market will grow robustly over the next ten years, driven primarily by ...


Dec 16, 2015, 10:00 ET PCSK9 Inhibitors Set to Achieve Blockbuster Status Despite Constraints on Use

Decision Resources Group finds that the recently launched proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor class will be a key driver...


Dec 10, 2015, 08:30 ET The PD-1 inhibitors, Keytruda (pembrolizumab) and Opdivo (nivolumab), are prescribed by three-quarters of surveyed U.S. oncologists for previously treated, unresectable or metastatic malignant melanoma

Decision Resources Group finds that the majority of U.S. surveyed oncologists are aware of Merck & Co.'s Keytruda (pembrolizumab) and Bristol-Myers...


Dec 09, 2015, 08:30 ET The Prostate Cancer Drug Therapy Market Will More Than Double in Size Over the Next Decade and Reach $13.8 Billion in 2024 Across the United States, Europe and Japan

Decision Resources Group finds that the prostate cancer drug therapy market will witness an impressive 9.6 percent annual growth over 2014-2024, with ...


Dec 08, 2015, 08:30 ET European Physicians Report Strong but Variable Uptake of All-Oral Interferon-Free Hepatitis C Virus Regimens Across EU5 Countries

Decision Resources Group finds that surveyed EU5 physicians report that more than half of their hepatitis C virus (HCV) patients were being treated...


Dec 07, 2015, 08:30 ET The Launch of Multiple First-in-Class Biologic Therapies will Transform the Chronic Pain Market Over the Next Decade

Decision Resources Group finds that the launch of novel biologic therapies targeting nerve growth factor (NGF) or, to a lesser extent, the calcitonin ...


Nov 30, 2015, 08:30 ET The Malignant Melanoma Market Will Double to $3 Billion in 2024, Fueled by Uptake of Immune Checkpoint Inhibitors and Combination Therapies

Decision Resources Group finds that immune checkpoint inhibitors, specifically CTLA-4 inhibitor Yervoy (Bristol-Myers Squibb/Ono Pharmaceutical), and ...


Nov 24, 2015, 08:30 ET Despite the Budget Strains Affecting EU5 Healthcare Systems, Commercial Opportunity Awaits New Antibiotics Targeting Multi-Drug-Resistant Bacteria

Decision Resources Group finds that variations in market access schemes across the EU5 countries (France, Germany, Italy, Spain and United Kingdom)...


Nov 19, 2015, 08:30 ET Novel Agents Contribute to Rapid Growth of Both the Type 2 Diabetes and Obesity Markets

Decision Resources Group finds that, according to analyses of U.S. longitudinal patient-level claims data in the Treatment Algorithms: Type 2...


Nov 12, 2015, 08:30 ET Personalized therapies and novel combination treatments in oncology often improve clinical outcomes; despite the inevitable associated premium prices, these developments can provide truly valuable advances and paradigm-shifting treatment practices

Decision Resources Group finds that cancer treatment is rapidly evolving and demand for more than modest incremental efficacy gains in highly...


Nov 11, 2015, 08:30 ET A Large Prevalent Population and the Lack of an Approved Therapeutic Highlight Lucrative Market Opportunity in Nonalcoholic Steatohepatitis

Decision Resources Group finds that the lack of a simple diagnostic test and low physician awareness coupled with the lack of therapeutics are all...


Nov 09, 2015, 08:30 ET Increases in Vaccination Rates and Inclusion in Advisory Committee for Immunization Practices Recommendations Are Key Growth Drivers in the U.S. Adult Vaccine Market

Decision Resources Group finds that 55 percent of surveyed physicians reported increased vaccination rates in the past twelve months across five...


Nov 06, 2015, 08:30 ET The US Neurostimulation device market will experience strong growth through 2024, driven primarily by innovation-based expansion of the eligible patient population and growth in sales of replacement units

Decision Resources Group finds that the neurostimulation device market in the US will grow robustly over the next ten years, driven primarily by a...


Nov 05, 2015, 08:30 ET Clinical Trial Design Improvements Could Spur Drug Development for Autism and Traumatic Brain Injury, While Biomarkers Appear Key in the Discovery of Treatments for Amyotrophic Lateral Sclerosis

Decision Resources Group finds that neurologists specializing in autism spectrum disorder (ASD) consider its heterogeneity a key obstacle to...


Nov 04, 2015, 08:30 ET Surveyed physicians report that acute kidney injury (AKI) is difficult to manage

Decision Resources Group finds that according to 44 percent of surveyed nephrologists and 37 percent of surveyed critical care physicians, AKI is...


Oct 30, 2015, 08:30 ET The Breast Cancer Market Will Capture Major-Market Sales of Almost $20 Billion in 2024, Driven by the Launch of Premium-Priced Therapies and Continued Uptake of Recent Entrants

Decision Resources Group finds that by 2024 the breast cancer market will have grown to almost $20 billion across the major markets (United States,...


Oct 29, 2015, 08:30 ET High Unmet Need, Low Patient Numbers and a Dearth of Available Treatment Options Underlie US Payers' Receptivity to High-Premium Priced Orphan Drugs

Decision Resources Group finds that more than half of surveyed US managed care organization (MCO) pharmacy and medical directors indicated incurring...


Oct 28, 2015, 08:30 ET The US and European contrast agent and radiopharmaceutical markets will expand over the next 10 years, propelled by ASP hikes in the radiopharmaceutical space and increasing diagnostic imaging procedures

Decision Resources Group finds that while some differences exist, the US and European contrast agent and radiopharmaceutical markets are similar and...


Oct 27, 2015, 08:30 ET The Market for Non-Small-Cell Lung Cancer Will Grow to $12.7 Billion in 2024, Driven by the Entry of Eleven Novel Drugs

Decision Resources Group finds that the entry of eleven novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's...